Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Dalhoff

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Anaerobe|July 13, 2014
In vitro activity of MCB3681 against Clostridium difficile strainsMamun-Ur Rashid, Axel Dalhoff, Andrej Weintraub, et al.
Antimicrobial Agents and Chemotherapy|January 18, 2018
Population Pharmacokinetics of Finafloxacin in Healthy Volunteers and Patients with Complicated Urinary Tract InfectionsMax Taubert, Mark Lückermann, Andreas Vente, et al.
Antimicrobial Agents and Chemotherapy|May 25, 2004
Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacinAlison K Meagher, Alan Forrest, Axel Dalhoff, et al.
Antimicrobial Agents and Chemotherapy|August 9, 2017
Pharmacokinetics of Intravenous Finafloxacin in Healthy VolunteersMax Taubert, Joseph Chiesa, Mark Lückermann, et al.
Antimicrobial Agents and Chemotherapy|November 24, 2005
Moxifloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against streptococcus pneumoniae in vitro when administered up to 6 hours after challengeMartina Ulrich, Cordula Albers, Jan-Georg Möller, et al.
International Journal of Antimicrobial Agents|June 17, 2014
Ecological impact of MCB3837 on the normal human microbiotaMamun-Ur Rashid, Axel Dalhoff, Tobias Bäckström, et al.
International Journal of Antimicrobial Agents|December 14, 2005
Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral doseFlorian M E Wagenlehner, Martina Kinzig-Schippers, Uwe Tischmeyer, et al.
Chemotherapy|March 2, 2011
Urinary pharmacokinetics and bactericidal activity of finafloxacin (200 and 800 mg) in healthy volunteers receiving a single oral doseFlorian M E Wagenlehner, Christine M Wagenlehner, Birgit Blenk, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Anaerobe|July 13, 2014
In vitro activity of MCB3681 against Clostridium difficile strainsMamun-Ur Rashid, Axel Dalhoff, Andrej Weintraub, et al.
Antimicrobial Agents and Chemotherapy|January 18, 2018
Population Pharmacokinetics of Finafloxacin in Healthy Volunteers and Patients with Complicated Urinary Tract InfectionsMax Taubert, Mark Lückermann, Andreas Vente, et al.
Antimicrobial Agents and Chemotherapy|May 25, 2004
Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacinAlison K Meagher, Alan Forrest, Axel Dalhoff, et al.
Antimicrobial Agents and Chemotherapy|August 9, 2017
Pharmacokinetics of Intravenous Finafloxacin in Healthy VolunteersMax Taubert, Joseph Chiesa, Mark Lückermann, et al.
Antimicrobial Agents and Chemotherapy|November 24, 2005
Moxifloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against streptococcus pneumoniae in vitro when administered up to 6 hours after challengeMartina Ulrich, Cordula Albers, Jan-Georg Möller, et al.
International Journal of Antimicrobial Agents|June 17, 2014
Ecological impact of MCB3837 on the normal human microbiotaMamun-Ur Rashid, Axel Dalhoff, Tobias Bäckström, et al.
International Journal of Antimicrobial Agents|December 14, 2005
Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral doseFlorian M E Wagenlehner, Martina Kinzig-Schippers, Uwe Tischmeyer, et al.
Chemotherapy|March 2, 2011
Urinary pharmacokinetics and bactericidal activity of finafloxacin (200 and 800 mg) in healthy volunteers receiving a single oral doseFlorian M E Wagenlehner, Christine M Wagenlehner, Birgit Blenk, et al.
Pageof 3